Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Review Article

Towards Better Drug Repositioning: Targeted Immunoinflammatory Therapy for Diabetic Nephropathy

Author(s): Qin Zhang, Ming Yang, Ying Xiao, Yachun Han, Shikun Yang and Lin Sun*

Volume 28 , Issue 5 , 2021

Published on: 08 November, 2019

Page: [1003 - 1024] Pages: 22

DOI: 10.2174/0929867326666191108160643

Price: $65

Abstract

Diabetic nephropathy (DN) is one of the most common and important microvascular complications of diabetes mellitus (DM). The main clinical features of DN are proteinuria and a progressive decline in renal function, which are associated with structural and functional changes in the kidney. The pathogenesis of DN is multifactorial, including genetic, metabolic, and haemodynamic factors, which can trigger a sequence of events. Controlling metabolic risks such as hyperglycaemia, hypertension, and dyslipidaemia is not enough to slow the progression of DN. Recent studies emphasized immunoinflammation as a critical pathogenic factor in the progression of DN. Therefore, targeting inflammation is considered a potential and novel treatment strategy for DN. In this review, we will briefly introduce the inflammatory process of DN and discuss the anti-inflammatory effects of antidiabetic drugs when treating DN.

Keywords: Diabetic nephropathy, immunoinflammatory, metformin, statins, glucagon-like peptide-1 analogue, spironolactone, phosphodiesterase inhibitors, vitamin D.


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy